Provided by Tiger Trade Technology Pte. Ltd.

Orchestra BioMed

4.17
+0.25006.38%
Volume:196.70K
Turnover:817.07K
Market Cap:235.46M
PE:-2.32
High:4.25
Open:3.94
Low:3.94
Close:3.92
52wk High:5.98
52wk Low:2.20
Shares:56.46M
Float Shares:32.02M
Volume Ratio:1.08
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7979
EPS(LYR):-1.6573
ROE:-166.97%
ROA:-52.21%
PB:5.38
PE(LYR):-2.52

Loading ...

Orchestra Biomed Unveils Vision for Growth With Updates on Pivotal Cardiovascular Trials and Strategic Partnerships

Reuters
·
Feb 06

Jefferies Sticks to Its Buy Rating for Orchestra BioMed Holdings (OBIO)

TIPRANKS
·
Jan 15

Orchestra BioMed to Receive Up to $21 Million from Vivasure Sale to Haemonetics

Reuters
·
Jan 12

Orchestra Biomed to Receive up to $21 Million in Proceeds From Acquisition of Vivasure by Haemonetics

THOMSON REUTERS
·
Jan 12

Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation

Reuters
·
Jan 10

Orchestra BioMed Holdings Is Maintained at Overweight by Barclays

Dow Jones
·
Jan 09

Orchestra BioMed Holdings (OBIO) Receives a Buy from Barclays

TIPRANKS
·
Jan 09

Orchestra BioMed Holdings Initiated at Buy by TD Cowen

Dow Jones
·
Dec 11, 2025

Orchestra Biomed Holdings Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $15

THOMSON REUTERS
·
Dec 10, 2025

BRIEF-Orchestra BioMed Announces AVIM Therapy And Virtue SAB Program Presentations At ICI Meeting

Reuters
·
Dec 08, 2025

Orchestra BioMed Showcases AVIM Therapy and Virtue SAB at ICI Meeting

Reuters
·
Dec 08, 2025

Orchestra Biomed Announces Avim Therapy and Virtue SAB Program Presentations at Ici Meeting

THOMSON REUTERS
·
Dec 08, 2025

BRIEF-Orchestra Biomed Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 27, 2025

Orchestra BioMed Grants Stock Options to New Hires Under Inducement Plan

Reuters
·
Nov 27, 2025

Orchestra BioMed Q3 EPS USD -0.4

Reuters
·
Nov 20, 2025

Orchestra BioMed Director and Officer David P. Hochman Reports Acquisition of Common Shares

Reuters
·
Nov 18, 2025

Orchestra BioMed Management Highlights Strategic Progress and $150 Million Financing in Corporate Update

Reuters
·
Nov 13, 2025

Orchestra BioMed Holdings Is Maintained at Overweight by Barclays

Dow Jones
·
Nov 13, 2025

Orchestra Biomed Holdings, Inc. : Barclays Cuts Target Price to $11 From $12

THOMSON REUTERS
·
Nov 12, 2025

Barclays Sticks to Their Buy Rating for Orchestra BioMed Holdings (OBIO)

TIPRANKS
·
Nov 12, 2025